Publications by authors named "Clement Charpentier"
Eur J Dermatol
April 2023
Article Synopsis
- The study compares the costs and overall survival (OS) of metastatic melanoma (MM) patients treated with conventional chemotherapy (2008-2012) versus new targeted therapies (2013-2017), revealing a median OS of 158 days for chemotherapy and 395 days for targeted therapies.
- The cost per patient for chemotherapy was €10,280, while targeted therapies cost significantly more at €94,676, indicating a substantial increase in healthcare expenditures with new treatments.
- Ultimately, the study concludes that while costs and life expectancy have risen, new targeted therapies are considered cost-effective, with an incremental cost-effectiveness ratio of €90,184 per life year gained.
